組織非形成性甲状腺癌薬の世界市場:化学療法、新規療法

◆英語タイトル:Global Anaplastic Thyroid Cancer Drugs Market 2019-2023
◆商品コード:IRTNTR31464
◆発行会社(リサーチ会社):Technavio
◆発行日:2019年6月19日
◆ページ数:124
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル、アジア太平洋、ヨーロッパ、中東・アフリカ、北米、南米
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥275,000見積依頼/購入/質問フォーム
Five User(5名様閲覧用)USD3,000 ⇒換算¥330,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD4,000 ⇒換算¥440,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はTechnavio社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Technavio社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

本調査レポートでは、組織非形成性甲状腺癌薬の世界市場について調べ、組織非形成性甲状腺癌薬の市場状況、市場規模、市場予測、市場環境、顧客状況、市場動向、関連企業情報などをまとめました。また、組織非形成性甲状腺癌薬の市場規模をセグメンテーション別(製品別(化学療法、新規療法))と地域別(グローバル、アジア太平洋、ヨーロッパ、中東・アフリカ、北米、南米)に分けて算出しました。
・サマリー
・レポートの範囲
・組織非形成性甲状腺癌薬の市場状況
・組織非形成性甲状腺癌薬の市場規模
・組織非形成性甲状腺癌薬の市場予測
・組織非形成性甲状腺癌薬の世界環境:ファイブフォース分析
・市場セグメンテーション:製品別(化学療法、新規療法)
・組織非形成性甲状腺癌薬の顧客状況
・主要地域別市場規模:グローバル、アジア太平洋、ヨーロッパ、中東・アフリカ、北米、南米
・意思決定フレームワーク
・市場動向・成長要因・課題
・関連企業状況・企業分析
 ...
【レポートの概要】

Global Anaplastic Thyroid Cancer Drugs Market: About this market

Technavio’s anaplastic thyroid cancer drugs market analysis considers sales from both chemotherapy and novel therapy. Our report also finds the sales of anaplastic thyroid cancer drugs in North America, Europe, Asia, and ROW. In 2018, chemotherapy segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as the high prevalence of thyroid cancer will play a significant role in the chemotherapy segment to maintain its market position. Also, our global anaplastic thyroid cancer drugs market report looks at factors such as the introduction of targeted therapies, and the rising geriatric population and high prevalence of thyroid cancer. However, the adverse effects of chemotherapy, availability of substitutes, and stringent regulations may hamper the growth of the anaplastic thyroid cancer drugs industry over the forecast period.

Global anaplastic thyroid cancer drugs market: Overview

Introduction of targeted therapies

The adverse effects associated with the off-label medicines available in the market has led to the development of targeted therapies for cancer treatments. The mutations of the BRAF gene cause most of the cases of anaplastic thyroid cancer. Hence, BRAF kinase inhibitors are one of the most foreseen small molecule targeted therapy drugs for the treatment of anaplastic thyroid cancer. Thus, the introduction of targeted therapies will lead to the expansion of the anaplastic thyroid cancer drugs market at a CAGR of more than 4% during the forecast period.

Reimbursement policies for chemotherapy

The high cost of off-label therapies such as chemotherapy remains a challenge for patients and the healthcare system. To overcome this challenge, governments and NGOs are focusing on providing financial assistance for the treatment of various cancer indications, including anaplastic thyroid cancer. This encourages many patients to avail off-label treatments, which will lead to an increase in the patient base. Thus, the increasing availability of reimbursement policies for chemotherapy will fuel market growth during the forecast period.

For the detailed list of factors that will drive the global anaplastic thyroid cancer drugs market during the forecast period 2019-2023, click here.

Competitive Landscape

With the presence of several major players, the global anaplastic thyroid cancer drugs market is moderately fragmented. Technavio’s robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading anaplastic thyroid cancer drugs manufacturers, that include Bristol-Myers Squibb Co., Celgene Corp., Eisai Co. Ltd., Johnson & Johnson Services Inc., and Novartis AG.

Also, the anaplastic thyroid cancer drugs market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

【レポートの目次】

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

2.1 Preface

2.2 Preface

2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

Market ecosystem

Market characteristics

Market segmentation analysis

PART 04: MARKET SIZING

Market definition

Market sizing 2018

Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

Bargaining power of buyers

Bargaining power of suppliers

Threat of new entrants

Threat of substitutes

Threat of rivalry

Market condition

PART 06: MARKET SEGMENTATION BY PRODUCT

Market segmentation by product

Comparison by product

Chemotherapy – Market size and forecast 2018-2023

Novel therapy – Market size and forecast 2018-2023

Market opportunity by product

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

Geographic segmentation

Geographic comparison

North America – Market size and forecast 2018-2023

Europe – Market size and forecast 2018-2023

Asia – Market size and forecast 2018-2023

ROW – Market size and forecast 2018-2023

Key leading countries

Market opportunity

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

Market drivers

Market challenges

PART 11:  MARKET TRENDS

PART 12: VENDOR LANDSCAPE

Overview

Landscape disruption

Competitive scenario

PART 13: VENDOR ANALYSIS

Vendors covered

Vendor classification

Market positioning of vendors

Bristol-Myers Squibb Co.

Celgene Corp.

Eisai Co. Ltd.

Johnson & Johnson Services Inc.

Novartis AG

PART 14: APPENDIX

Research methodology

List of abbreviations

Definition of market positioning of vendors

PART 15: EXPLORE TECHNAVIO

LOE

Exhibit 01:Global oncology therapeutics market

Exhibit 02:Segments of global oncology therapeutics market

Exhibit 03:Market characteristics

Exhibit 04:Market segments

Exhibit 05:Market definition – Inclusions and exclusions checklist

Exhibit 06:Market size 2018

Exhibit 07:Global market: Size and forecast 2018-2023 ($ millions)

Exhibit 08:Global market: Year-over-year growth 2019-2023 (%)

Exhibit 09:Five forces analysis 2018

Exhibit 10:Five forces analysis 2023

Exhibit 11:Bargaining power of buyers

Exhibit 12:Bargaining power of suppliers

Exhibit 13:Threat of new entrants

Exhibit 14:Threat of substitutes

Exhibit 15:Threat of rivalry

Exhibit 16:Market condition – Five forces 2018

Exhibit 17:Product – Market share 2018-2023 (%)

Exhibit 18:Comparison by product

Exhibit 19:Chemotherapy – Market size and forecast 2018-2023 ($ millions)

Exhibit 20:Chemotherapy – Year-over-year growth 2019-2023 (%)

Exhibit 21:Novel therapy – Market size and forecast 2018-2023 ($ millions)

Exhibit 22:Novel therapy – Year-over-year growth 2019-2023 (%)

Exhibit 23:Patient assistance programs

Exhibit 24:Market opportunity by product

Exhibit 25:Customer landscape

Exhibit 26:Market share by geography 2018-2023 (%)

Exhibit 27:Geographic comparison

Exhibit 28:North America – Market size and forecast 2018-2023 ($ millions)

Exhibit 29:North America – Year-over-year growth 2019-2023 (%)

Exhibit 30:Top 3 countries in North America

Exhibit 31:Europe – Market size and forecast 2018-2023 ($ millions)

Exhibit 32:Europe – Year-over-year growth 2019-2023 (%)

Exhibit 33:Top 3 countries in Europe

Exhibit 34:Asia – Market size and forecast 2018-2023 ($ millions)

Exhibit 35:Asia – Year-over-year growth 2019-2023 (%)

Exhibit 36:Top 3 countries in Asia

Exhibit 37:ROW – Market size and forecast 2018-2023 ($ millions)

Exhibit 38:ROW – Year-over-year growth 2019-2023 (%)

Exhibit 39:Top 3 countries in ROW

Exhibit 40:Key leading countries

Exhibit 41:Market opportunity

Exhibit 42:Global growth in geriatric population in the last five years (%)

Exhibit 43:Adverse effects associated with available drugs for treatment of anaplastic thyroid cancer

Exhibit 44:Impact of drivers and challenges

Exhibit 45:Drug development pipeline: Late-stage molecules for anaplastic thyroid cancer

Exhibit 46:Vendor landscape

Exhibit 47:Landscape disruption

Exhibit 48:Vendors covered

Exhibit 49:Vendor classification

Exhibit 50:Market positioning of vendors

Exhibit 51:Bristol-Myers Squibb Co. – Vendor overview

Exhibit 52:Bristol-Myers Squibb Co. – Product segments

Exhibit 53:Bristol-Myers Squibb Co. – Organizational developments

Exhibit 54:Bristol-Myers Squibb Co. – Geographic focus

Exhibit 55:Bristol-Myers Squibb Co. – Key offerings

Exhibit 56:Bristol-Myers Squibb Co. – Key customers

Exhibit 57:Celgene Corp. – Vendor overview

Exhibit 58:Celgene Corp. – Business segments

Exhibit 59:Celgene Corp. – Organizational developments

Exhibit 60:Celgene Corp. – Geographic focus

Exhibit 61:Celgene Corp. – Key offerings

Exhibit 62:Celgene Corp. – Key customers

Exhibit 63:Eisai Co. Ltd. – Vendor overview

Exhibit 64:Eisai Co. Ltd. – Business segments

Exhibit 65:Eisai Co. Ltd. – Organizational developments

Exhibit 66:Eisai Co. Ltd. – Geographic focus

Exhibit 67:Eisai Co. Ltd. – Segment focus

Exhibit 68:Eisai Co. Ltd. – Key offerings

Exhibit 69:Eisai Co. Ltd. – Key customers

Exhibit 70:Johnson & Johnson Services, Inc. – Vendor overview

Exhibit 71:Johnson & Johnson Services, Inc. – Business segments

Exhibit 72:Johnson & Johnson Services, Inc. – Organizational developments

Exhibit 73:Johnson & Johnson Services, Inc. – Geographic focus

Exhibit 74:Johnson & Johnson Services, Inc. – Segment focus

Exhibit 75:Johnson & Johnson Services, Inc. – Key offerings

Exhibit 76:Johnson & Johnson Services, Inc. – Key customers

Exhibit 77:Novartis AG – Vendor overview

Exhibit 78:Novartis AG – Business segments

Exhibit 79:Novartis AG – Organizational developments

Exhibit 80:Novartis AG – Geographic focus

Exhibit 81:Novartis AG – Segment focus

Exhibit 82:Novartis AG – Key offerings

Exhibit 83:Novartis AG – Key customers

Exhibit 84:Validation techniques employed for market sizing

Exhibit 85:Definition of market positioning of vendors



【掲載企業】

Bristol-Myers Squibb Co.、Celgene Corp.、Eisai Co. Ltd.、Johnson & Johnson Services Inc.、Novartis AG

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[組織非形成性甲状腺癌薬の世界市場:化学療法、新規療法]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆